Tagged parnell-pharmaceuticals
Press Release
Parnell Pharmaceuticals Holdings Ltd Announces New CDMO Agreement and Business Update
Parnell announces a new contract manufacturing agreement for one animal health product and a memorandum of understanding for two additional products with a global multi-national; revenue in the first half of 2019 down 12% compared to 2018 due to timing of technology transfer revenues versus prior year; and holds 2019 guidance for a 17 - 25% increase over 2018 revenue and an EBITDA range of $7.5 - $8.5m. Read More
Press Release
Parnell Pharmaceuticals Holdings Ltd Announces Business Results for the Quarter Ended 31 March 2019
Parnell delivers 9% revenue growth in Quarter 1 of 2019 compared to 2018, and confirms provisional 2019 guidance for a 17 - 25% increase over 2018 revenue to $31 - $33 million and an EBITDA range of $7.5 - $8.5 million subject to winning at least one new Contract Manufacturing agreement in 2019. Read More
Press Release
